NC
ONCY

NewSquare Capital’s Oncolytics Biotech ONCY Stock Holding History

NewSquare Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-220
Closed -$572 – 806
2023
Q2 		$572 Sell
220
-1,000
-82% -$1.66K ﹤0.01% 673
2023
Q1 		$1.46K Hold
1,220
– – ﹤0.01% 605
2022
Q4 		$1.99K Buy
+1,220
New +$1.85K ﹤0.01% 481

Other funds holding ONCY

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NewSquare Capital's ONCY Position: Q3 2023 in Review

NewSquare Capital sold out of Oncolytics Biotech (ONCY) in Q3 2023, closing a stake of 220 shares — an estimated $572 sold.

NewSquare Capital first reported a position in ONCY in Q4 2022 and held it in 3 quarters. The position peaked at $1.99K in Q4 2022. 33 funds tracked by Wall St. Rank hold ONCY as of Q3 2023.

  • NewSquare Capital reported no remaining Oncolytics Biotech position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 220 Oncolytics Biotech shares in Q3 2023, an estimated $572.
  • NewSquare Capital first reported a position in Oncolytics Biotech in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Oncolytics Biotech position peaked at $1.99K in Q4 2022.
  • 33 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.